参考文献/References:
[1]孔嘉宁,张彬彬,施军平.《代谢相关（非酒精性）脂肪性肝病防治指南（2024年版）》解读[J].临床肝胆病杂志,2024,40(9):1767-1770.
[2]WEI S，WANG L，EVANS P C，et al.NAFLD and NASH:Etiology,targets and emerging therapies[J].Drug Discov Today,2024,29(3):103910.
[3]WAN S K,CHAN K W,YUSOFF M F M,et al.Correspondence:A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J].Ann Hepatol，2024,29(4):101485.
[4]GRUZDEV K S,PODOPRIGORA V I,GIZINGER A O.Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD):Mechanisms,bacteria,and novel therapeutic targets[J].Arch Microbiol，2024,206(2):62.
[5]SHI Y,CHEN J,QU D,et al.Ginsenoside 5 activates the LKB1/AMPK/mTOR signaling pathway and modifies the gut microbiota to alleviate nonalcoholic fatty liver disease induced by a high-fat diet[J].Nutrients,2024,16(6):842.
[6]SCHNEIDER K M,MOHS A,GUI W,et al.Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment[J].Nat Commun，2022,13(1):3964.
[7]吴永娜,张磊,陈拓,等.人体肠道微生态与肝脏免疫关系研究进展[J].中国微生态学杂志,2021,33(2):227-230.
[8]刘云霄,窦婧,王晓忠.基于“调和肝脾”论述肝纤维化与肠道菌群的关系[J].临床肝胆病杂志,2023,39(2):278-283.
[9]马艺鑫,宁顺宇,吕晓明,等.基于“肝脾相关”理论探讨疏肝健脾法调控肠道微生态防治糖脂代谢性疾病[J].时珍国医国药,2020,31(10):2450-2452.
[10]潘杰,刘来浩,牟建伟.肠道菌群与人类健康研究进展[J].山东师范大学学报(自然科学版),2021,36(4):337-365.
[11]王玉栎,刘畅,牛辰,等.肠道菌群影响非酒精性脂肪性肝病的机制及应对策略[J].微生物与感染,2021,16(5):347-355.
[12]于子真,吴仪,谭周进.特征肠道菌群在中医方证中的研究现状及意义[J].中国微生态学杂志,2023,35(4):489-493.
[13]祝思思,王炳予,杨磊,等.不同中医证型非酒精性脂肪性肝炎患者肠道菌群差异性研究[J].中国中西医结合消化杂志,2023,31(10):781-787.
[14]中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗指南(基层医生版)[J].中西医结合肝病杂志,2019,29(5):483-486.
[15]许亚辉,吴佳佳,李杰,等.肝郁脾虚证与肠道菌群相关研究[J].世界科学技术-中医药现代化,2018,20(11):1958-1963.
[16]WU H,LOU T Y,PAN M X,et al.Chaihu Guizhi Ganjiang decoction attenuates nonalcoholic steatohepatitis by enhancing intestinal barrier integrity and ameliorating PPARα mediated lipotoxicity[J].J.Ethnopharmacol,2024,326：117841.
[17]贾琛琛,岳蓉,向文雯,等.基于“肠-肝轴”探讨逍遥散加味方对代谢相关脂肪性肝病小鼠肠道屏障及肠道菌群的影响[J].中国中药杂志,2024,49(16):4499-4509.
[18]HUI D C,LIU L,AZAMI N L B,et al.The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial[J].Front Endocrinol,2023,13：1107071.
[19]庞会婷.中药田黄方通过肠道菌群改善NAFLD的作用及机制研究[D].广州：广东药科大学,2021.
[20]朱春胜,施亚敏,付智慧,等.基于肠道菌群和代谢组学研究化滞柔肝颗粒治疗非酒精性脂肪肝的作用机制[J].中草药,2023,54(4):1190-1200.
[21]CHEN P L,ZHANG F L,LIU S,et al.Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota[J].Microbiol Spectr,2024,e0197923.
[22]ZHANG F Q,WU J S,RUAN H N,et al.Zexie decoction alleviates non-alcoholic fatty liver disease in rats:The study of genes,lipids,and gut microbiotas[J].Biochem Biophys Res Commun,2022,632:129-138.
[23]寇少杰,薛敬东,杨栓住,等.运脾化浊颗粒治疗非酒精性脂肪肝的临床效果及对患者肠道菌群的影响[J].临床医学研究与实践,2022,7(10):115-117.
[24]YAN J B,NIE Y M,LIU Y,et al.Yiqi-Bushen-Tiaozhi recipe attenuated high-fat and high-fructose diet induced nonalcoholic steatohepatitis in mice via gut microbiota[J].Front Cell Infect Microbiol,2022,12:824597.
[25]JIANG Y F,YUE R S,TAN Y Y,et al.Gynostemma pentaphyllumextract alleviates NASH in mice:Exploration of inflammation and gut microbiota[J].Nutrients,2024,16(11):1782.
[26]MA S S,YANG B,SHI Y C,et al.Adlay (Coix lacryma-jobi L.) polyphenol improves hepatic glucose and lipid homeostasis through regulating intestinal flora via AMPK pathway[J].Molecular Nutrition & Food Research,2022,66(23):e2200447.
[27]XU H L,YUAN M M,NIU K L,et al.Involvement of bile acid metabolism and gut microbiota in the amelioration of experimental metabolism-associated fatty liver disease by nobiletin[J].Molecules,2024,29(5):976.
[28]程成,张军峰,史丽云.湿热证与肠道微生态[J].南京中医药大学学报,2018,34(2):210-213.
[29]TAN Y Y,HUANG Z H,LIU Y Y,et al.Integrated serum pharmacochemistry,16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease[J].J Ethnopharmacol,2023,310:116418.
[30]张森.基于肠-肝轴研究决明子乙醇提取物改善非酒精性脂肪性肝病的作用及机制[D].南昌：南昌大学,2022.
[31]DING X Q,JIAN T Y,LI J W,et al.Chicoric acid ameliorates nonalcoholic fatty liver disease via the AMPK/Nrf2/NF-κB signaling pathway and restores gut microbiota in High-Fat-Diet-Fed mice[J].Oxid Med Cell Longev,2020,17:9734560.
[32]李璐,王玉琳,秦鸿宇,等.小檗碱调节肠肝轴治疗非酒精性脂肪肝病的研究进展[J].中草药,2021,52(5):1501-1509.
[33]罗科学,潘智敏,张永乐,等.调脂积冲剂对痰瘀互结证代谢综合征患者肠道菌群结构的影响[J].中华全科医学,2018,16(5):744-747.
[34]刘巧红.祛湿化瘀方治疗非酒精性脂肪性肝病湿热蕴结证患者的临床疗效评价及对肠道菌群紊乱的调节作用[D].上海：上海中医药大学,2021.
[35]LI H S,XI Y F,XIN X,et al.Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis[J].Biomed & Pharmacother,2020,124:109915.
[36]YAN G M,ZHANG L N,WU D Q,et al.Paeonol attenuates nonalcoholic steatohepatitis by regulating intestinal flora and AhR/NLRP3/Caspase-1 metabolic pathway[J].J Ethnopharmacol,2024,329:118147.
[37]ZHU L J,XIAO M M,LUO J G,et al.Polysaccharides from ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE/ mice[J].Int J Biol Macromol,2023,235:123853.
相似文献/References:
[1]黄 飞,闫小光△,刘铜华.糖肾汤对代谢综合征患者肠道菌群影响的研究*[J].陕西中医,2019,(12):1713.
[2]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(6):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[3]唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,(10):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
TANG Yinghui,YE Miaoqing,HE Jinyu,et al.Huazhi Fugan granule alleviates Kupffer cell inflammation by inhibiting TLR4/NF-κB/NLRP3 and improves nonalcoholic fatty liver disease[J].,2022,(6):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
[4]林先佳,王小锋,张媛媛,等.基于网络药理学和分子对接探讨肝脂平治疗非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(4):524.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.027]
[5]龚璐天,宋 卓,许 云,等.基于正邪平衡理论探讨肠道菌群在肿瘤免疫治疗中的双向作用[J].陕西中医,2023,(6):751.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.015]
GONG Lutian,SONG Zhuo,XU Yun,et al.The bidirectional effect of intestinal flora in tumor immunotherapy was discussed based on the theory of healthy qi and pathogenic qi balance[J].,2023,(6):751.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.015]
[6]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮调节AMPK/Nrf2信号通路治疗小鼠非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(8):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Mechanism of cryptotanshinone regulates AMPK/Nrf2 signaling pathway to treat nonalcoholic fatty liver disease in mouse[J].,2023,(6):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
[7]杨 帆,李 娟,何 昉,等.利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响[J].陕西中医,2023,(10):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
YANG Fan,LI Juan,HE Fang,et al.Lidan Tuihuang decoction on liver function,glycolipid metabolism,and serum adipose factors in the treatment of non alcoholic fatty liver disease[J].,2023,(6):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
[8]李秀秀,张玉佩,许春玲,等.基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点[J].陕西中医,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
LI Xiuxiu,ZHANG Yupei,XU Chunling,et al.Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism[J].,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
[9]罗 艺,周晓玲,刘 琳,等.非酒精性脂肪性肝病中医治疗研究进展[J].陕西中医,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
LUO Yi,ZHOU Xiaoling,LIU Lin,et al.Research progress on traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J].,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
[10]李木兰,石丹丹,张毅,等.茵陈蒿汤不同煎煮法对大鼠非酒精性脂肪性肝病疗效的影响研究[J].陕西中医,2025,46(6):741.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.004]
LI Mulan,SHI Dandan,ZHANG Yi,et al.Therapeutic effect of different decocting methods of Yinchenhao decoction on non-alcoholic fatty liver disease rats[J].,2025,46(6):741.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.004]